BACKGROUND: The contribution of CD8(+) lymphocytes to the pathogenesis of cardiac allograft vasculopathy, or chronic rejection in heart transplants, remains undefined. We used both major histocompatibility complex class I mismatched and major histocompatibility complex class II mismatched models of cardiac allograft vasculopathy to characterize the role of CD8(+) lymphocytes in the development of cardiac allograft vasculopathy. METHODS: Donor hearts from B10.A mice were transplanted into B10.BR recipients (major histocompatibility complex class I mismatched). Donor hearts were harvested at 1, 7, 14, and 30 days after transplantation and (1) quantitated morphometrically for lesion development, (2) stained immunohistochemically, or (3) digested for isolation of graft-infiltrating cells. The cytotoxic phenotype of graft-infiltrating CD8(+) lymphocytes was determined with flow cytometry. Intracellular cytokine staining of CD8(+) and CD4(+) lymphocytes for interleukin 2, interferon g, interleukin 4, and interleukin 10 was performed with 2-color flow cytometry. Finally, B6.C-H2(bm12) donor hearts were transplanted into either C57BL/6 wild-type (major histocompatibility complex class II mismatched) or CD8 -/- knockout recipients and examined for the development of cardiac allograft vasculopathy. RESULTS: In the major histocompatibility complex class I mismatched model, CD8(+) lymphocytes were the predominant T-lymphocyte subset that infiltrated the allografts and demonstrated markers of activation. The intracellular cytokine-staining assay demonstrated that CD8(+) lymphocytes were the primary sources of allograft interleukin 2 and interferon gamma. Intimal lesions developed in the allografts by day 14 (12.0% +/- 4.0%) and further increased by day 30 (44.0% +/- 5.0%). In the major histocompatibility complex class II mismatched model, the donor hearts in the CD8 -/- knockout recipients had substantially less severe intimal lesions when compared with the donor hearts in wild-type recipients (19.0% +/- 6.0% vs 50.0% +/- 7.0%, respectively; P <.05). CONCLUSIONS: In both major histocompatibility complex class I and II mismatched models, CD8(+) lymphocytes contribute significantly to chronic rejection. The findings of this study suggest that control of chronic rejection requires interventions directed at CD8(+) lymphocytes.
BACKGROUND: The contribution of CD8(+) lymphocytes to the pathogenesis of cardiac allograft vasculopathy, or chronic rejection in heart transplants, remains undefined. We used both major histocompatibility complex class I mismatched and major histocompatibility complex class II mismatched models of cardiac allograft vasculopathy to characterize the role of CD8(+) lymphocytes in the development of cardiac allograft vasculopathy. METHODS:Donor hearts from B10.A mice were transplanted into B10.BR recipients (major histocompatibility complex class I mismatched). Donor hearts were harvested at 1, 7, 14, and 30 days after transplantation and (1) quantitated morphometrically for lesion development, (2) stained immunohistochemically, or (3) digested for isolation of graft-infiltrating cells. The cytotoxic phenotype of graft-infiltrating CD8(+) lymphocytes was determined with flow cytometry. Intracellular cytokine staining of CD8(+) and CD4(+) lymphocytes for interleukin 2, interferon g, interleukin 4, and interleukin 10 was performed with 2-color flow cytometry. Finally, B6.C-H2(bm12) donor hearts were transplanted into either C57BL/6 wild-type (major histocompatibility complex class II mismatched) or CD8 -/- knockout recipients and examined for the development of cardiac allograft vasculopathy. RESULTS: In the major histocompatibility complex class I mismatched model, CD8(+) lymphocytes were the predominant T-lymphocyte subset that infiltrated the allografts and demonstrated markers of activation. The intracellular cytokine-staining assay demonstrated that CD8(+) lymphocytes were the primary sources of allograft interleukin 2 and interferon gamma. Intimal lesions developed in the allografts by day 14 (12.0% +/- 4.0%) and further increased by day 30 (44.0% +/- 5.0%). In the major histocompatibility complex class II mismatched model, the donor hearts in the CD8 -/- knockout recipients had substantially less severe intimal lesions when compared with the donor hearts in wild-type recipients (19.0% +/- 6.0% vs 50.0% +/- 7.0%, respectively; P <.05). CONCLUSIONS: In both major histocompatibility complex class I and II mismatched models, CD8(+) lymphocytes contribute significantly to chronic rejection. The findings of this study suggest that control of chronic rejection requires interventions directed at CD8(+) lymphocytes.
Authors: David K Cole; Pierre J Rizkallah; Malkit Sami; Nikolai M Lissin; Feng Gao; John I Bell; Jonathan M Boulter; Meir Glick; Anne Lise Vuidepot; Bent K Jakobsen; George F Gao Journal: Acta Crystallogr Sect F Struct Biol Cryst Commun Date: 2005-02-12
Authors: James J Yun; Michael P Fischbein; David Whiting; Yoshihito Irie; Michael C Fishbein; Marie D Burdick; John Belperio; Robert M Strieter; Hillel Laks; Judith A Berliner; Abbas Ardehali Journal: Am J Pathol Date: 2002-10 Impact factor: 4.307
Authors: Sahil Shah; Saeed Daneshmandi; Kevin R Hughes; Shuangjin Yu; Angela M Bedoya; Lonnie D Shea; Xunrong Luo Journal: Biomaterials Date: 2019-05-01 Impact factor: 12.479
Authors: Xueli Yuan; Jesus Paez-Cortez; Isabela Schmitt-Knosalla; Francesca D'Addio; Bechara Mfarrej; Michela Donnarumma; Antje Habicht; Michael R Clarkson; John Iacomini; Laurie H Glimcher; Mohamed H Sayegh; M Javeed Ansari Journal: J Exp Med Date: 2008-12-01 Impact factor: 14.307
Authors: Vera Usuelli; Moufida Ben Nasr; Francesca D'Addio; Kaifeng Liu; Andrea Vergani; Basset El Essawy; Jun Yang; Emma Assi; Mayuko Uehara; Chiara Rossi; Anna Solini; Annalisa Capobianco; Elena Rigamonti; Luciano Potena; Massimo Venturini; Mario Sabatino; Lorena Bottarelli; Enrico Ammirati; Maria Frigerio; Eduardo Castillo-Leon; Anna Maestroni; Cinzia Azzoni; Cristian Loretelli; Andy Joe Seelam; Albert K Tai; Ida Pastore; Gabriella Becchi; Domenico Corradi; Gary A Visner; Gian V Zuccotti; Nelson B Chau; Reza Abdi; Marcus G Pezzolesi; Paolo Fiorina Journal: Am J Transplant Date: 2021-05-03 Impact factor: 9.369